Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
What we know about the Brown University shooting suspect who was found dead, and how police linked him to the MIT killing - 2The Developing Nearby Food Development and Its Advantages
- 3When does Spotify Wrapped come out? The music streamer says 'soon.'
- 47 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
- 5Figure out How to Score Huge with Open Record Rewards
- Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
- UK consumer confidence plunges amid escalating Iran conflict
- What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- NASA will bring space station crew home early after medical issue
- Historical mysteries solved by science in 2025
- Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- Launch pad damaged as Russian rocket blasts off for space station, agency says
- Japanese H3 rocket fails during launch of navigation satellite (video)
- Most loved Road Food: Which One Prevails upon You?
